NCT02169089
Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial
See it on ClinicalTrials.gov ↗79 people
41.8%
58.2%
33 womenmiddle line = equal numbers46 men
- Phase
- PHASE4
- Paid for by
- University Hospitals Cleveland Medical Center
- Finished
- 2022-04-29
- Health conditions
- Atherosclerosis
- Who could join
- Anyone
- Ages
- 41 Years – no maximum
- Average age
- mean 64.3 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Black / African American 58.2% · White 38% · Not reported 3.8% · American Indian / Alaska Native 0% · Asian 0% · Native Hawaiian / Pacific Islander 0% · More than one race 0%
Women left out
- No pregnant women
Women who were pregnant could not join.
“Pregnant women and nursing mothers.”
- No breastfeeding moms
Women who were breastfeeding could not join.
“Pregnant women and nursing mothers.”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“. Any surgical or medical condition which might alter pharmacokinetics of drug (e.g. renal transplant, liver failure, liver transplant).”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia.”
- No diabetes
Women with diabetes were turned away.
“Type I diabetes mellitus”
- No cancer
Women with current or past cancer were turned away.
“History of prior malignancy including leukemia and lymphoma (but not basal cell skin cancer, cured squamous cell cancer and localized Prostate cancer).”
Study titles and rules are shown in their original English.